Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Conditions
BCR-JAK2 Fusion Protein Expression · Blasts 20 Percent or Less of Peripheral Blood White Cells · Blasts More Than 5 Percent of Bone Marrow Nucleated Cells · Blasts More Than 5 Percent of Peripheral Blood White Cells · Blasts Under 20 Percent of Bone Marrow Nucleated Cells · Chronic Eosinophilic Leukemia, Not Otherwise Specified · Eosinophilia · Hepatomegaly · Hypereosinophilic Syndrome · JAK2 Gene Mutation · Splenomegaly · TEL-JAK2 Fusion Protein Expression
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
Contact: Principal Investigator (William E Shomali)OHSU Knight Cancer Institute, Portland, Oregon, United States
University of Utah, Salt Lake City, Utah, United States
Fred Hutchinson cancer research center, Seattle, Washington, United States
Study leads
William E Shomali, MD
Principal Investigator
Stanford Cancer Institute Palo Alto